Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
- Astellas will open a new state-of-the-art life sciences facility in Cambridge, Mass.
- The facility will occupy two floors, approximately 62,000 square feet.
- The building is targeting LEED Gold and WiredScore Platinum certifications.
- Astellas expects a few hundred Boston-based employees to operate out of the new building.
- None.
TOKYO and
Designed by Ennead and Jacobs Consulting, 441 Morgan is the fifth lab-ready building at CX and is situated at a gateway to the neighborhood with views of the Charles River and beyond. With wellness, connectivity, and tenant experience at the forefront, when complete, 441 Morgan will offer five outdoor terraces, direct access to a five-acre park, integrated building technologies including smart technology View Glass, three underground levels of parking and a bike room.
Astellas expects to occupy two floors, or approximately 62,000 square feet, of the new facility in 2024. Astellas will house both laboratory and office areas. The laboratory area will be occupied by Discovery Accelerator, which will serve as an additional incubator space for external collaborators as well as Mitobridge. Over time, a few hundred
As part of Astellas' and DivcoWest's commitments to sustainability and reducing its environmental impact, the building is targeting LEED Gold. The building is also targeting WiredScore Platinum certifications and is ideally situated just steps to two MBTA lines, including the Community College orange line station and the Lechmere green line station.
Astellas was represented by Transwestern Real Estate Services Executive Vice Presidents Kyle Robbins and David Burkards and Executive Managing Director Andrew Davidson.
Tadaaki Taniguchi, M.D., Ph.D., Chief Medical Officer, Astellas
"This investment in
Mark Roopenian, Managing Director, DivcoWest
"We are thrilled to welcome Astellas to Cambridge Crossing. Through thoughtful and purposeful design, CX has become home to some of the world's leading life science and biotech companies offering both the built environment forward-thinking companies need for today's research and development, and the vibrant community employees desire. We look forward to Astellas being part of the neighborhood and a collaborative partner."
Yoshitsugu Shitaka, Ph.D., Chief Scientific Officer, Astellas
"Our new
About Astellas' actions in the
Over the past couple years, Astellas has been growing its presence in the
Astellas' vision is to create an innovation network across
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.
About DivcoWest
Founded in 1993 by Stuart Shiff, DivcoWest, a DivCore Capital company, is a vertically integrated real estate investment firm headquartered in
Cautionary Notes (Astellas)
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/astellas-to-open-new-life-sciences-facility-in-divcowests-cambridge-crossing-neighborhood-301896677.html
SOURCE Astellas Pharma Inc.
FAQ
What is Astellas Pharma planning to do in Cambridge, Mass?
How much space will Astellas occupy in the new facility?
What certifications is the building targeting?
How many employees will operate out of the new building?